Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.38 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316833 | 0.78 | SMN1; SMN2 (0.56) | ALDH1A1CRHR1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL6696477 | 0.76 | LMNA (0.41) | KDM4EMAPTTP53GAASMN1; SMN2 | |
| SCHEMBL6693184 | 0.74 | MAPK14 (0.35) | ALDH1A1MAPTGAAATMPTGS2 | |
| SCHEMBL8151831 | 0.74 | MAPT (0.35) | KDM4EALDH1A1MAPTATM | |
| SCHEMBL6694812 | 0.73 | MAPT (0.36) | KDM4EALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL6697459 | 0.71 | KMT2A (0.39) | KDM4EALDH1A1MAPTPOLBGAA | |
| SCHEMBL6698332 | 0.70 | KMT2A (0.40) | KDM4EALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL6703138 | 0.70 | MAPT (0.41) | KDM4EALDH1A1MAPTCYP1A2CYP3A4 | |
| SCHEMBL6696470 | 0.70 | MAPT (0.38) | KDM4EALDH1A1MAPTTP53POLB | |
| SCHEMBL6693074 | 0.69 | SYK (0.36) | KDM4EALDH1A1MAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835726-B2 | Pyrimidine derivatives | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040006068-A1 | Pyrimidine derivatives | TULARIK INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1056742-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041253-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | KDM4E 1947/4885ALDH1A1 2001/4885CRHR1 4562/4885 |
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | KDM4E 2819/4885ALDH1A1 2587/4885CRHR1 4794/4885 |
| US-20040006068-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | KDM4E 2819/4885ALDH1A1 2587/4885CRHR1 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.